Telix Pharmaceuticals (TLX) administered the first patient dose in an early trial of TLX300-CDx, also known as olaratumab, to treat advanced metastatic soft tissue sarcoma.
The trial aims to evaluate the drug's safety, how it moves through and interacts with the body, and the distribution of radiation within tissues, as well as determine the optimal dose, the company said Tuesday in a statement.
Additionally, the trial will help finalize the choice of therapeutic radionuclide to pair with the drug candidate, the company said.
TLX300-CDx hasn't received marketing authorization in any jurisdiction, the company said.
Price: 16.71, Change: -0.05, Percent Change: -0.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.